Anti-tumour necrosis factor therapy for ulcerative colitis: Evidence to date

Drugs

Volumn 66, Issue 16, 2006, Pages 2059-2065

  Thukral, Chandrashekhar ^a   Cheifetz, Adam ^a   Peppercorn, Mark A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DELMITIDE; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HISTOPLASMOSIS; HUMAN; ILEITIS; INFECTION; LUPUS LIKE SYNDROME; NEUROLOGIC DISEASE; NONHUMAN; OPTIC NEURITIS; POLYNEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ULCERATIVE COLITIS; DRUG ANTAGONISM; REVIEW;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; HUMANS; POUCHITIS; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847709966     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666160-00002     Document Type: Article

References (31)

1. Farrell RJ, Banerjee S, Peppercorn MA. Recent advances in inflammatory bowel disease. Crit Rev Clin Lab Sci 2001; 38: 33-108
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29
3. Hanauer S. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-92
4. Hanauer S, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9
5. Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004; 126: 1574-81
6. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumor necrosis factor in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7
7. Schurmann G, Betzler M, Post S, et al. Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes in serum concentrations. Digestion 1992; 51: 51-9
8. Masuda H, Iwai S, Tanaka T, et al. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995; 46: 111-23
9. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81
10. Watkins PE, Warren BF, Stephens S, et al. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997; 40: 628-33
11. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001; 7 Suppl. 1: S30-3
12. Kaser A, Mairinger T, Vogel W, et al. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001; 113: 930-3
13. Kohn A, Prantera C, Pera A, et al. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open label study on 13 patients. Dig Liv Dis 2002; 34: 626-30
14. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 2577-84
15. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006; 40: 476-81
16. Ochsenkuhn T, Sackmann M, Goeke B. Infliximab for acute, non steroid refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004; 16: 1167-71
17. Armuzzi A, De Pascalis B, Lupascu P, et al. Infliximab in the treatment of steroid dependant ulcerative colitis. Eur Rev Med Pharmacol Sci 2004; 8: 213-33
18. Armuzzi A, Lupascu P, De Pascalis B, et al. Infliximab in the treatment of glucocorticoid dependant ulcerative colitis: a 54-week randomized methylprednisolone-controlled trial [abstract]. Gastroenterology 2005; 128 Suppl. 2: W1008
19. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut 2003; 52: 998-1002
20. Actis GC, Bruno M, Pinna-Pintor M, et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002; 34: 631-4
21. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-8
22. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11
23. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76
24. Fazio VW, Zuv Y, Church JM, et al. Ileal pouch-anal anastomosis: complications and function in 1005 patients. Ann Surg 1995; 222: 120-7
25. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis and treatment. Gastroenterology 1994, 60
26. Shen B, Fazio VW, Remzi FH, et al. Clinical approaches to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol 2005; 100: 2796-807
27. Viscido A, Habib FI, Kohn A, et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 2003; 17: 1263-71
28. Evans RC, Clarke L, Heath P, et al. Treatment of ulcerative colitis with an engineered human anti-TNF alpha antibody CDP571. Aliment Pharmacol Ther 1997; 11: 1031-5
29. Iyer S, Kontoyiannis D, Chevrier D, et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem 2000; 275: 17051-7
30. Iyer S, Lahana R, Buelow R. Rational design and development of RDP58. Curr Pharm Des 2002; 8: 2217-29
31. Travis S, Yap L, Hawkey CJ. Novel and effective therapy for ulcerative colitis: results of parallel, prospective, placebo-controlled trials [abstract]. Am J Gastroenterol 2003; 98: S239